心脏骤停可电击心律患者的低温治疗与常温治疗:TTM-2研究二次分析
本研究为TTM-2随机临床试验的事后分析,纳入与既往显示低温获益的随机试验特征相似的可电击心律院外心脏骤停患者,比较33°C低温与常温(目标<37.8°C)治疗。共600例患者纳入分析(低温组294例,常温组306例)。6个月生存率低温组70.4% vs 常温组71.8%(RR 0.96,95%CI 0.81-1.15,P=0.71),良好功能结局(mRS 0-3)低温组67.3% vs 常温组66.0%(RR 1.03,95%CI 0.87-1.23,P=0.79),均无显著差异。低温组心律失常发生率显著高于常温组(21.2% vs 14.1%,OR 1.49,95%CI 1.05-2.14,P=0.026)。
要点
- 在特征类似既往低温获益研究的可电击心律OHCA患者中,33°C低温组6个月生存率70.4% vs 常温组71.8%(RR 0.96,95%CI 0.81-1.15,P=0.71),无显著差异。
- 良好功能结局(mRS 0-3)低温组67.3% vs 常温组66.0%(RR 1.03,95%CI 0.87-1.23,P=0.79),无显著差异。
- 低温组心律失常发生率21.2%(62/294)显著高于常温组14.1%(43/306),OR 1.49(95%CI 1.05-2.14),P=0.026。
- 该分析为TTM-2试验的事后分析,共纳入600例(占TTM-2总1891例的31.7%),低温组294例,常温组306例。
适用人群与场景
- 纳入TTM-2试验中与既往一项显示低温获益的随机试验特征相似的可电击心律院外心脏骤停(OHCA)患者,共600例(低温组294例,常温组306例)。
处置流程与药物剂量
- 低温组目标温度33°C,常温组目标温度<37.8°C。
研究设计与关键结果
- 研究类型:TTM-2(NCT02908308)实用、多中心、随机临床试验的事后分析;共纳入600例患者(占TTM-2总1891例的31.7%),低温组294例,常温组306例。
- 主要终点:6个月生存率低温组70.4%(207/294) vs 常温组71.8%(220/306),RR 0.96(95%CI 0.81-1.15),P=0.71。
- 次要终点:6个月良好功能结局(mRS 0-3)低温组67.3%(198/294) vs 常温组66.0%(202/306),RR 1.03(95%CI 0.87-1.23),P=0.79。
- 不良事件:心律失常发生率低温组21.2%(62/294) vs 常温组14.1%(43/306),OR 1.49(95%CI 1.05-2.14),P=0.026。
证据类型、等级与局限
- 证据类型:随机对照试验(TTM-2)的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为:在心脏骤停特征类似既往低温获益研究的可电击心律患者中,33°C低温治疗未改善6个月生存或功能结局,且心律失常事件增加。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The aim of this study was to assess whether hypothermia increased survival and improved functional outcome when compared with normothermia in out-of-hospital cardiac arrest (OHCA) patients with similar characteristics than in previous randomized studies showing benefits for hypothermia.
METHODS: Post hoc analysis of a pragmatic, multicenter, randomized clinical trial (TTM-2, NCT02908308). In this analysis, the subset of patients included in the trial who had similar characteristics to patients included in one previous randomized trial and randomized to hypothermia at 33 °C or normothermia (i.e. target < 37.8 °C) were considered. The primary outcome was survival at 6 months; secondary outcomes included favorable functional outcome at 6 months, defined as a modified Rankin scale of 0-3. Time-to-death and the occurrence of adverse events were also reported.
RESULTS: From a total of 1891 included in the TTM-2 study, 600 (31.7%) were included in the analysis, 294 in the hypothermia and 306 in the normothermia group. At 6 months, 207 of the 294 patients (70.4%) in the hypothermia group and 220 of the 306 patients (71.8%) in the normothermia group had survived (relative risk with hypothermia, 0.96; 95% confidence interval [CI], 0.81 to 1.15; P = 0.71). Also, 198 of the 294 (67.3%) in the hypothermia group and 202 of the 306 (66.0%) in the normothermia group had a favorable functional outcome (relative risk with hypothermia, 1.03; 95% CI, 0.87 to 1.23; P = 0.79). There was a significant increase in the occurrence of arrythmias in the hypothermia group (62/294, 21.2%) when compared to the normothermia group (43/306, 14.1%-OR 1.49, 95% CI 1.05-2.14; p = 0.026).
CONCLUSIONS: In this study, hypothermia at 33˚C did not improve survival or functional outcome in a subset of patients with similar cardiac arrest characteristics to patients in whom benefit from hypothermia was shown in prior studies.
参考来源
- Taccone FS, Cariou A, Zorzi S, et al. Hypothermia versus normothermia in patients with cardiac arrest and shockable rhythm: a secondary analysis of the TTM-2 study. Crit Care. 2024. PMID: 39407230. doi:10.1186/s13054-024-05119-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。